Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • November 7th, 2014 • Durata Therapeutics, Inc. • Pharmaceutical preparations
This License Agreement (“Agreement”), effective as of July 29, 2014 (the “Effective Date”), is made by and between Durata Therapeutics International B.V. (“B.V.”), a company registered in the Netherlands with offices at Spaces Zuidas II, Barbara Strozzilaan 101, 1083 HN Amsterdam, the Netherlands (“Durata”) and A.C.R.A.F. S.p.A., a company with only one shareholder under direction and coordination of Finaf S.p.A., a company duly organized and validly existing under the laws of Italy, with its principal place of business at Viale Amelia , 70 - 00181 Rome Italy (“Angelini”). Capitalized terms not otherwise defined herein shall have the meanings set forth in ARTICLE I.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SECOND AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • November 7th, 2014 • Durata Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT is entered into this 22nd day of August, 2014, by and between Gnosis Bioresearch srl., a subsidiary fully owned company by GNOSIS SPA organized under the laws of Italy whose head office is located at Via Pomarico, 75010 Pisticci Scalo (MT), Italy, which is registered in the Commercial Register of Matera under No. 01023770777 (“Gnosis”), and Durata Therapeutics International B.V., a company registered in the Netherlands, with offices at Spaces Zuidas II, Barbara Strozzliaan 101, 1083 HN Amsterdam, the Netherlands (“Durata”) (collectively the “Parties”).
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2014 • Durata Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “Amendment”) to that certain Employment Agreement by and between Durata Therapeutics, Inc. and John Shannon (“Executive”), effective as of June 20, 2012 (the “Agreement”), is made and entered into July 29, 2014 (the “Amendment Effective Date”). Certain capitalized term shall have the meaning ascribed to them in the Agreement.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUPPLY AGREEMENTSupply Agreement • November 7th, 2014 • Durata Therapeutics, Inc. • Pharmaceutical preparations
This Supply Agreement (“Agreement”), effective as of July 29, 2014 (the “Effective Date”), is made by and between Durata Therapeutics International B.V., a company registered in the Netherlands with offices at Spaces Zuidas II, Barbara Strozzilaan 101, 1083 HN Amsterdam, the Netherlands (“Durata”) and A.C.R.A.F. S.p.A.—a company with only one shareholder under direction and coordination of Finaf S.p.A., a company duly organized and validly existing under the laws of Italy, with its principal place of business at Viale Amelia, 70—00181 Rome Italy (“Angelini”).
